Nuo Therapeutics and PAM Health Collaborate to Enhance Regenerative Wound Healing Access

HOUSTON, April 17, 2025 – Patients dealing with chronic wounds within the PAM Health network will soon benefit from a groundbreaking treatment designed to speed up healing. Thanks to a long-term exclusive agreement between PAM Health and Nuo Therapeutics, Inc., Nuo’s Aurix System will be the primary platelet-rich plasma (PRP) therapy used in PAM Health’s long-term acute care hospitals, rehabilitation centers, and outpatient and wound care clinics. This partnership aims to make advanced regenerative treatments more accessible to those suffering from chronic wounds that do not heal easily.

Chronic wounds affect nearly 2% of the U.S. population annually, impacting over 8 million Medicare beneficiaries, as stated by Nussbaum et al., 2018. This condition places a significant financial strain on the healthcare system, with Medicare costs related to wound care ranging from $28.1 to $96.8 billion each year. Beyond the economic impact, the human cost is severe, with over 100,000 diabetic patients facing amputations yearly. Furthermore, the mortality rate within five years post-amputation is nearly 62% (Armstrong et al., 2017).

Dave Hazard, Vice President of Sales at Nuo, emphasized that the collaboration with PAM Health extends beyond mere product distribution. It represents a shared mission to expand access to the Aurix System due to PAM Health's extensive clinical presence in 23 states. Together, the goal is to minimize complications, enhance healing durations, and ultimately improve patient outcomes.

The Aurix System stands out as the first FDA-cleared autologous PRP therapy specifically for managing chronic wounds. It features a streamlined, one-minute process to create a biologically active gel from a patient's own platelets and plasma, aiding the natural healing cycle. Clinical studies, including those partnered with the Centers for Medicare & Medicaid Services, have shown Aurix’s effectiveness in hastening healing compared to other advanced wound care methods.

Nick Fazzolari, Senior Vice President and Chief Business Officer at PAM Health, stated their dedication to delivering clinical excellence through evidence-based therapies. Integrating the Aurix System into their advanced wound care services is a testament to their commitment to innovative, patient-focused solutions that optimize healing, minimize complications, and support long-term health. This collaboration aligns seamlessly with PAM Health’s mission to provide transformative care solutions consistently.

PAM Health, operating over 100 hospitals and specialty clinics, continues to set a high standard by merging data-driven innovation with compassionate care. The inclusion of Aurix PRP into their wound care services is part of a broader strategy to offer comprehensive, cost-effective care for patients with complex and chronic conditions, particularly those at risk of limb loss and repeated hospital admissions.

Nuo Therapeutics, Inc. is a company at the forefront of biodynamic therapies, leveraging the body’s natural healing capacities. Their flagship Aurix System is an FDA-cleared autologous PRP therapy designed for chronic wound management.

Based in Enola, Pennsylvania, PAM Health delivers post-acute healthcare services through more than 100 facilities across 23 states. The organization remains committed to high-quality patient care and exceptional customer service, with a dedicated staff striving to be the most trusted healthcare provider in every community served.